131 related articles for article (PubMed ID: 10052962)
1. Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonists.
Keenan RM; Callahan JF; Samanen JM; Bondinell WE; Calvo RR; Chen L; DeBrosse C; Eggleston DS; Haltiwanger RC; Hwang SM; Jakas DR; Ku TW; Miller WH; Newlander KA; Nichols A; Parker MF; Southhall LS; Uzinskas I; Vasko-Moser JA; Venslavsky JW; Wong AS; Huffman WF
J Med Chem; 1999 Feb; 42(4):545-59. PubMed ID: 10052962
[TBL] [Abstract][Full Text] [Related]
2. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
Okumura K; Shimazaki T; Aoki Y; Yamashita H; Tanaka E; Banba S; Yazawa K; Kibayashi K; Banno H
J Med Chem; 1998 Oct; 41(21):4036-52. PubMed ID: 9767641
[TBL] [Abstract][Full Text] [Related]
3. From peptide to non-peptide. 3. Atropisomeric GPIIbIIIa antagonists containing the 3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione nucleus.
Blackburn BK; Lee A; Baier M; Kohl B; Olivero AG; Matamoros R; Robarge KD; McDowell RS
J Med Chem; 1997 Feb; 40(5):717-29. PubMed ID: 9057858
[TBL] [Abstract][Full Text] [Related]
4. Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.
Sall DJ; Arfsten AE; Bastian JA; Denney ML; Harms CS; McCowan JR; Morin JM; Rose JW; Scarborough RM; Smyth MS; Um SL; Utterback BG; Vasileff RT; Wikel JH; Wyss VL; Jakubowski JA
J Med Chem; 1997 Aug; 40(18):2843-57. PubMed ID: 9288166
[TBL] [Abstract][Full Text] [Related]
5. Fibrinogen receptor (GPIIb-IIIa) antagonists derived from 5,6-bicyclic templates. Amidinoindoles, amidinoindazoles, and amidinobenzofurans containing the N-alpha-sulfonamide carboxylic acid function as potent platelet aggregation inhibitors.
Su T; Naughton MA; Smyth MS; Rose JW; Arfsten AE; McCowan JR; Jakubowski JA; Wyss VL; Ruterbories KJ; Sall DJ; Scarborough RM
J Med Chem; 1997 Dec; 40(26):4308-18. PubMed ID: 9435900
[TBL] [Abstract][Full Text] [Related]
6. Preparation and biological activity of novel tricyclic GPIIb/IIIa antagonists.
Robarge KD; Dina MS; Somers TC; Lee A; Rawson TE; Olivero AG; Tischler MH; Webb RR; Weese KJ; Aliagas I; Blackburn BK
Bioorg Med Chem; 1998 Dec; 6(12):2345-81. PubMed ID: 9925295
[TBL] [Abstract][Full Text] [Related]
7. Design of a new class of orally active fibrinogen receptor antagonists.
Klein SI; Molino BF; Czekaj M; Gardner CJ; Chu V; Brown K; Sabatino RD; Bostwick JS; Kasiewski C; Bentley R; Windisch V; Perrone M; Dunwiddie CT; Leadley RJ
J Med Chem; 1998 Jul; 41(14):2492-502. PubMed ID: 9651154
[TBL] [Abstract][Full Text] [Related]
8. GPIIb/IIIa integrin antagonists with the new conformational restriction unit, trisubstituted beta-amino acid derivatives, and a substituted benzamidine structure.
Hayashi Y; Katada J; Harada T; Tachiki A; Iijima K; Takiguchi Y; Muramatsu M; Miyazaki H; Asari T; Okazaki T; Sato Y; Yasuda E; Yano M; Uno I; Ojima I
J Med Chem; 1998 Jun; 41(13):2345-60. PubMed ID: 9632368
[TBL] [Abstract][Full Text] [Related]
9. Corticotropin-releasing hormone receptor antagonists: framework design and synthesis guided by ligand conformational studies.
Hodge CN; Aldrich PE; Wasserman ZR; Fernandez CH; Nemeth GA; Arvanitis A; Cheeseman RS; Chorvat RJ; Ciganek E; Christos TE; Gilligan PJ; Krenitsky P; Scholfield E; Strucely P
J Med Chem; 1999 Mar; 42(5):819-32. PubMed ID: 10072680
[TBL] [Abstract][Full Text] [Related]
10. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part III: synthesis of potent antagonists with alpha(v)beta3/alpha(IIb)beta3 dual activity and improved water solubility.
Ishikawa M; Hiraiwa Y; Kubota D; Tsushima M; Watanabe T; Murakami S; Ouchi S; Ajito K
Bioorg Med Chem; 2006 Apr; 14(7):2131-50. PubMed ID: 16307881
[TBL] [Abstract][Full Text] [Related]
11. Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.
Olson RE; Sielecki TM; Wityak J; Pinto DJ; Batt DG; Frietze WE; Liu J; Tobin AE; Orwat MJ; Di Meo SV; Houghton GC; Lalka GK; Mousa SA; Racanelli AL; Hausner EA; Kapil RP; Rabel SR; Thoolen MJ; Reilly TM; Anderson PS; Wexler RR
J Med Chem; 1999 Apr; 42(7):1178-92. PubMed ID: 10197962
[TBL] [Abstract][Full Text] [Related]
12. Theoretical structure-activity studies of benzodiazepine analogues. Requirements for receptor affinity and activity.
Loew GH; Nienow JR; Poulsen M
Mol Pharmacol; 1984 Jul; 26(1):19-34. PubMed ID: 6087115
[TBL] [Abstract][Full Text] [Related]
13. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 2: synthesis of potent alpha(v)beta3/alpha(IIb)beta3 dual antagonists.
Ishikawa M; Kubota D; Yamamoto M; Kuroda C; Iguchi M; Koyanagi A; Murakami S; Ajito K
Bioorg Med Chem; 2006 Apr; 14(7):2109-30. PubMed ID: 16309912
[TBL] [Abstract][Full Text] [Related]
14. Quinazolines and 1,4-benzodiazepines. 92. Conformational recognition of the receptor by 1,4-benzodiazepines.
Blount JF; Fryer RI; Gilman NW; Todaro LJ
Mol Pharmacol; 1983 Nov; 24(3):425-8. PubMed ID: 6314115
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of gamma-MSH analogues at the human melanocortin MC3, MC4, and MC5 receptors. Discovery of highly selective hMC3R, hMC4R, and hMC5R analogues.
Balse-Srinivasan P; Grieco P; Cai M; Trivedi D; Hruby VJ
J Med Chem; 2003 Nov; 46(23):4965-73. PubMed ID: 14584947
[TBL] [Abstract][Full Text] [Related]
16. A three-residue cyclic scaffold of non-RGD containing peptide analogues as platelet aggregation inhibitors: design, synthesis, and structure--function relationships.
Stavrakoudis A; Bizos G; Eleftheriadis D; Kouki A; Panou-Pomonis E; Sakarellos-Daitsiotis M; Sakarellos C; Tsoukatos D; Tsikaris V
Biopolymers; 2000-2001; 56(1):20-6. PubMed ID: 11582574
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.
Mehrotra MM; Heath JA; Smyth MS; Pandey A; Rose JW; Seroogy JM; Volkots DL; Nannizzi-Alaimo L; Park GL; Lambing JL; Hollenbach SJ; Scarborough RM
J Med Chem; 2004 Apr; 47(8):2037-61. PubMed ID: 15056002
[TBL] [Abstract][Full Text] [Related]
18. The anti-platelet approach targeting the fibrinogen ligand of the GPIIB/IIIa receptor.
Tsikaris V
J Pept Sci; 2004 Oct; 10(10):589-602. PubMed ID: 15526708
[TBL] [Abstract][Full Text] [Related]
19. Structural characterization of a cyclic dipeptidomimetic: the effect of ring size on a 1,2,5-trisubstituted-3-oxo-1,4-diazepine system.
Piserchio A; Han Y; Chorev M; Mierke DF
Biopolymers; 2002 Jun; 64(1):16-25. PubMed ID: 11948438
[TBL] [Abstract][Full Text] [Related]
20. Molecular structure of Ro15-1788 and a model for the binding of benzodiazepine receptor ligands. Structural identification of common features in antagonists.
Codding PW; Muir AK
Mol Pharmacol; 1985 Aug; 28(2):178-84. PubMed ID: 2991738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
